Tumorigenic properties of alternative osteopontin isoforms in mesothelioma

Biochemical and Biophysical Research Communications

Volumn 382, Issue 3, 2009, Pages 514-518

  Ivanov, Sergey V ^a   Ivanova, Alla V ^a   Goparaju, Chandra M V ^a   Chen, Yuanbin ^a   Beck, Amanda ^a   Pass, Harvey I ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Differential splicing; Mesothelioma; Osteopontin

Indexed keywords

OSTEOPONTIN;

ARTICLE; ASSAY; CARCINOGENIC ACTIVITY; CELL LINE; CELL PROLIFERATION; EVALUATION; HUMAN; HUMAN CELL; MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PLEURA; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION; WOUND CLOSURE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; MOLECULAR SEQUENCE DATA; OSTEOPONTIN; PLEURA; PROTEIN ISOFORMS; RNA, MESSENGER; SOLITARY FIBROUS TUMOR, PLEURAL; UP-REGULATION;

EID: 64049117132     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.03.042     Document Type: Article

References (11)

1. Pass H.I., Lott D., Lonardo F., Harbut M., Liu Z., Tang N., Carbone M., Webb C., and Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 353 (2005) 1564-1573
2. Rangaswami H., Bulbule A., and Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16 (2006) 79-87
3. Pass H.I., Stevens E.J., Oie H., Tsokos M.G., Abati A.D., Fetsch P.A., Mew D.J., Pogrebniak H.W., and Matthews W.J. Characteristics of nine newly derived mesothelioma cell lines. Ann. Thorac. Surg. 59 (1995) 835-844
4. Cappia S., Righi L., Mirabelli D., Ceppi P., Bacillo E., Ardissone F., Molinaro L., Scagliotti G.V., and Papotti M. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am. J. Clin. Pathol. 130 (2008) 58-64
5. Mack P.C., Redman M.W., Chansky K., Williamson S.K., Farneth N.C., Lara Jr. P.N., Franklin W.A., Le Q.T., Crowley J.J., and Gandara D.R. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J. Clin. Oncol. 26 (2008) 4771-4776
6. Le Q.T., Chen E., Salim A., Cao H., Kong C.S., Whyte R., Donington J., Cannon W., Wakelee H., Tibshirani R., Mitchell J.D., Richardson D., O'Byrne K.J., Koong A.C., and Giaccia A.J. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 12 (2006) 1507-1514
7. El-Tanani M.K. Role of osteopontin in cellular signaling and metastatic phenotype. Front. Biosci. 13 (2008) 4276-4284
8. Ramaiah S.K., and Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 103 (2008) 4-13
9. Cantor H., and Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. (2008)
10. He B., Mirza M., and Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25 (2006) 2192-2202
11. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., and Weber G.F. Osteopontin-c is a selective marker of breast cancer. Int. J. Cancer 122 (2008) 889-897